Genmab Secures Milestone Payment In Janssen Collaboration
This article was originally published in Scrip
Executive Summary
Danish biotech Genmab A/S has secured a $45m milestone after the first US commercial sale of Darzalex (daratumumab) in its collaboration with Johnson & Johnson's Janssen Biotech, Inc.